Marvel Biosciences Corp (TSE:MRVL) has released an update.
Marvel Biosciences Corp. has extended its partnership with the iBraiN Institute to explore the effectiveness of their drug MB204 in a pre-clinical Rett syndrome model, following its earlier success in treating autism. This new phase of research will compare MB204 against the recently approved Rett syndrome drug Trofinetide. The company is optimistic that this work could lead to a significant therapeutic advancement for Rett syndrome and other autism spectrum disorders.
For further insights into TSE:MRVL stock, check out TipRanks’ Stock Analysis page.
